Source:http://linkedlifedata.com/resource/pubmed/id/18575192
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2008-6-25
|
| pubmed:abstractText |
Programmes that monitor local, national and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and provide feedback on the success of HIV-1 treatment and prevention programmes. The World Health Organization (WHO) has established a global programme for genotypic surveillance of HIV-1 drug resistance and has recommended the adoption of a consensus definition of genotypic drug resistance. Such a definition is necessary to accurately compare transmitted drug resistance rates across geographical regions and time periods. HIV-1 diversity and the large number of mutations associated with antiretroviral drug resistance complicate the development of a consensus definition for genotypic drug resistance. This paper reviews the data that must be considered to determine which of the many HIV-1 drug resistance mutations are likely to be both sensitive and specific indicators of transmitted drug resistance. The process used to create a previously published list of drug resistance mutations for HIV-1 surveillance is reviewed and alternative approaches to this process are discussed.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1359-6535
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13 Suppl 2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
59-68
|
| pubmed:dateRevised |
2011-9-22
|
| pubmed:meshHeading |
pubmed-meshheading:18575192-Anti-Retroviral Agents,
pubmed-meshheading:18575192-Cluster Analysis,
pubmed-meshheading:18575192-DNA Mutational Analysis,
pubmed-meshheading:18575192-Databases, Genetic,
pubmed-meshheading:18575192-Developing Countries,
pubmed-meshheading:18575192-Drug Resistance, Viral,
pubmed-meshheading:18575192-Epidemiologic Research Design,
pubmed-meshheading:18575192-Genotype,
pubmed-meshheading:18575192-HIV Infections,
pubmed-meshheading:18575192-HIV-1,
pubmed-meshheading:18575192-Humans,
pubmed-meshheading:18575192-Mutation,
pubmed-meshheading:18575192-National Health Programs,
pubmed-meshheading:18575192-Online Systems,
pubmed-meshheading:18575192-Phylogeny,
pubmed-meshheading:18575192-Polymorphism, Genetic,
pubmed-meshheading:18575192-Population Surveillance,
pubmed-meshheading:18575192-Program Development,
pubmed-meshheading:18575192-Terminology as Topic,
pubmed-meshheading:18575192-Treatment Outcome,
pubmed-meshheading:18575192-World Health,
pubmed-meshheading:18575192-World Health Organization
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.
|
| pubmed:affiliation |
Division of Infectious Diseases, Stanford University, Stanford, CA, USA. rshafer@stanford.edu
|
| pubmed:publicationType |
Journal Article,
Review,
Research Support, N.I.H., Extramural
|